Salmeterol-induced desensitization, internalization and phosphorylation of the human β2-adrenoceptor

被引:57
作者
January, B
Seibold, A
Allal, C
Whaley, BS
Knoll, BJ
Moore, RH
Dickey, BF
Barber, R
Clark, RB
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77225 USA
[2] Baylor Coll Med, VA Med Ctr, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, VA Med Ctr, Dept Cell Biol, Houston, TX 77030 USA
[4] Baylor Coll Med, VA Med Ctr, Dept Mol Physiol & Biophys, Houston, TX 77030 USA
[5] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
关键词
salmeterol; beta(2)-adrenoceptor; desensitization; internalization; phosphorylation;
D O I
10.1038/sj.bjp.0701658
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Partial agonists of the beta(2)-adrenoceptor which activate adenylyl cyclase are widely used as bronchodilators for the relief of bronchoconstriction accompanying many disease conditions, including bronchial asthma. The bronchodilator salmeterol has both a prolonged duration of action in bronchial tissue and the ability to reassert this activity following the temporary blockade of human beta(2)-adrenoceptors with antagonist. 2 We have compared the activation and desensitization of human beta(2)-adrenoceptor stimulation of adenylyl cyclase induced by salmeterol, adrenaline and salbutamol in a human lung epithelial line, BEAS-2B, expressing beta(2)-adrenoceptor levels of 40-70 fmol mg(-1), and in human embryonic kidney (HEK) 293 cell lines expressing 2-10 pmol mg(-1). The efficacy observed for the stimulation of adenylyl cyclase by salmeterol was only congruent to 10% of that observed for adrenaline in BEAS-2B cells expressing low levels of beta(2)-adrenoceptor, but similar to adrenaline in HEK 293 cells expressing very high levels of receptors. Salmeterol pretreatment of these cells induced a rapid and stable activation of adenylyl cyclase activity which resisted extensive washing and beta(2)-adrenoceptor antagonist blockade, consistent with binding to a receptor exosite and/or to partitioning into membrane lipid. 3 The desensitization and internalization of beta(2)-adrenoceptors induced by the partial agonists salmeterol and salbutamol were considerably reduced relative to the action of adrenaline. Consistent with these observations, the initial rate of phosphorylation of the receptor induced by salmeterol and salbutamol was much reduced in comparison to adrenaline. 4 Our data suggest that the reduction in the rapid phase of desensitization of beta(2)-adrenoceptors after treatment with salmeterol or salbutamol is caused by a decrease in the rate of beta(2)-adrenoceptor kinase (beta ARK) phosphorylation and internalization. In contrast, the fate of cyclic AMP-dependent protein kinase (PKA)-mediated phosphorylation by these partial agonists appears to be similar to adrenaline.
引用
收藏
页码:701 / 711
页数:11
相关论文
共 46 条
[1]   FORMOTEROL - PHARMACOLOGY, MOLECULAR-BASIS OF AGONISM, AND MECHANISM OF LONG-DURATION OF A HIGHLY POTENT AND SELECTIVE BETA(2)-ADRENOCEPTOR AGONIST BRONCHODILATOR [J].
ANDERSON, GP .
LIFE SCIENCES, 1993, 52 (26) :2145-2160
[2]  
Anderson P, 1996, LUNG, V174, P159
[3]   SALMETEROL, A NOVEL, LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST - CHARACTERIZATION OF PHARMACOLOGICAL ACTIVITY INVITRO AND INVIVO [J].
BALL, DI ;
BRITTAIN, RT ;
COLEMAN, RA ;
DENYER, LH ;
JACK, D ;
JOHNSON, M ;
LUNTS, LHC ;
NIALS, AT ;
SHELDRICK, KE ;
SKIDMORE, IF .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) :665-671
[4]   BETA-ADRENERGIC RECEPTORS AND THEIR REGULATION [J].
BARNES, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (03) :838-860
[5]  
BENOVIC JL, 1988, J BIOL CHEM, V263, P3893
[6]  
BERGENDAHL A, 1995, BRIT J PHARMACOL, V117, P1009
[7]  
BERGENDAL A, 1995, AM J RESP CRIT CARE, V151, pA272
[8]  
BHAGAT R, 1995, CHEST, V108, P159
[9]   LONG-TERM EFFECTS OF A LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSIVENESS IN PATIENTS WITH MILD ASTHMA [J].
CHEUNG, D ;
TIMMERS, MC ;
ZWINDERMAN, AH ;
BEL, EH ;
DIJKMAN, JH ;
STERK, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1198-1203
[10]  
CLARK RB, 1989, MOL PHARMACOL, V36, P343